Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to -$8.8 million.

  • Akebia Therapeutics' Change in Account Payables fell 191.16% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 763.49%. This contributed to the annual value of -$1.4 million for FY2024, which is 73.99% up from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Account Payables stood at -$8.8 million for Q3 2025, which was down 336.99% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Account Payables registered a high of $18.9 million during Q4 2022, and its lowest value of -$13.8 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Account Payables was -$2.2 million (2025), whereas its average is -$1.3 million.
  • Per our database at Business Quant, Akebia Therapeutics' Change in Account Payables plummeted by 272.51% in 2021 and then soared by 491.65% in 2022.
  • Akebia Therapeutics' Change in Account Payables (MRQ) stood at $3.2 million in 2021, then skyrocketed by 491.65% to $18.9 million in 2022, then crashed by 76.20% to $4.5 million in 2023, then tumbled by 46.84% to $2.4 million in 2024, then plummeted by 468.76% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q3 2025, $3.7 million for Q2 2025, and -$2.2 million during Q1 2025.